Hormone Support Given to Reduce Menopausal Complaints After Ovarian Cancer Treatment Surprisingly Prolonged Survival

Ovarian cancer in women leads to two problems. The first is the difficulties of surgery and chemotherapy; the second is reduced estrogen, the female hormone, following surgical removal of the ovaries, and the resulting deterioration in quality of life. The most important treatment for ovarian cancer is surgical removal of the ovaries followed by protective chemotherapy to reduce the likelihood of recurrence. Menopausal symptoms such as hot flashes caused by the loss of ovaries, and therefore estrogen, after surgery can substantially reduce quality of life.
Studies to date have mostly focused on prolonging life (survival). Menopausal complaints due to hormonal changes after surgery for ovarian cancer in premenopausal women, and the resulting deterioration in quality of life, have not been sufficiently examined.
As is known, hormone replacement therapy means giving menopausal women the missing hormone as oral tablets to reduce menopause-related complaints. The potential cancer risk of hormone replacement therapy used to reduce menopausal complaints in healthy individuals has been questioned for years, and we have always viewed these treatments cautiously. Although hormone replacement therapy increases uterine cancer risk somewhat, studies have not produced evidence that this hormonal support increases ovarian cancer risk.
An important study answering precisely this question was published in the Journal of Clinical Oncology, one of America's most respected medical journals. With an average follow-up of nearly 20 years, approximately 150 patients who had undergone ovarian cancer surgery were monitored. They were divided into two groups: one received hormone replacement after ovarian cancer treatment, replacing the missing hormone, while the other was observed after treatment.
The researchers initially expected improved quality of life without an adverse effect on survival, but the results surprised both them and us. The study found the anticipated improvement in quality of life, but also longer survival among those receiving hormone therapy; conversely, survival was shorter in those not using hormonal treatment.
It is naturally difficult to conclude from this study that all patients undergoing ovarian cancer surgery should immediately receive hormone support. Other studies are needed to support this result, but we can at least say that hormonal treatment can be given safely when severe menopausal complaints seriously impair quality of life after ovarian cancer treatment is completed. However, hormone replacement therapy has a recognized possible breast cancer risk, which must be considered in a benefit–risk assessment. This study did not find evidence that hormone replacement therapy increased breast cancer risk.
Sources
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
J Clin Oncol. 2015 Sep 28. pii: JCO.2015.60.9719.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.